Clinical Trial Update: Efficacy and Safety of SIL-8301 for Control of Hemolysis in a Uniform Sickle Cell Disease Endotype [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial evaluating SIL-8301 for control of hemolysis in a uniform sickle cell disease endotype is not yet recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Sickle Cell Disease

Drugs mentioned

• SIL-8301

Snippet

Sponsor: Biossil Inc. | Conditions: Sickle Cell Disease, Sickle Cell Anaemia | Phase 2 | Status: NOT_YET_RECRUITING